Objective
to report the 5-year clinical outcomes of treatment of aortic valve stenosis in patients at immediate surgical risk with self-expanding transcatheter valve replacement (TAVR) as compared to surgery
Study
prospective, multicentre, randomised study
Population
patients with symptomatic severe aortic stenosis
Endpoints
all-cause death and disabling stroke at 5 years


Conclusion
the incidence of all-cause death and disabling strokes at 5 years was not different between treatment with TAVR or surgery in patients with symptomatic severe aortic stenosis at intermediate surgical risk
van Mieghem et al. JAMA Cardiol. 2022;7:1000-08